Global Coalition On Your editorial “Vinay Prasad’s Vaccine Kill Shot” (Review & Outlook, Feb. 12) points out that a recent decision by Mr. Prasad, the leader of the Food and Drug Administration’s vaccine division, will have negative consequences.
Mr. Prasad’s decision to reject Moderna’s flu vaccine without even reviewing it is even worse than you describe. Denying us a new, innovative flu vaccine is horrible health policy. Innovation is at risk because, as Moderna’s CEO has said, if the largest market is off limits, investments won’t be made.
But the decision will also have economic consequences. Investment in preventive health is critical as our population ages. In its April 2025 World Economic Outlook report, the International Monetary Fund dedicated an entire chapter to the need for healthier longevity as the global population ages.
Healthy aging affects labor markets. We can expect labor shortages unless older adults can continue to work. The IMF advises the pursuit of policies that emphasize health promotion and prevention measures.
The IMF report recognizes that to ensure a robust 21st-century workforce and fuel economic activity generally, those of us over 55 must be able to play a part. We can’t do so if we’re not given the tools for healthier longevity.
Mr. Prasad’s decision to reject Moderna’s flu vaccine therefore not only has health implications but could have an effect on labor shortages in America’s aging society.